NCT00967538 - Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic Treatments | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Psoriasis

Interventions

DRUG

etanercept 50 mg

All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.

Trial Locations (16)

Kirk Barber Research, Calgary

PerCuro Clinical Research Ltd, Victoria

Winnipeg Clinic Dermatology Research, Winnipeg

Nexus Clinical Research, St. John's

New Lab Clinical Research, St. John's

Eastern Canada Cutaneous Research Associates Ltd, Halifax

Sudbury Skin Clinic, Greater Sudbury

Dermatrials Research, Hamilton

Mediprobe Research Inc., London

Lynderm research Inc., Markham

Dermatology Associates, North York

Dr. Jay Brian Taradash, Toronto

Innovaderm Research Inc., Montreal

Siena Medical Research, Montreal

Centre de Recherches Dermatologiques du Quebec Metropolitain, Québec

Clinique Esthetique Dr Isabelle Delorme, Saint-Hyacinthe